Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating ...

The nod for Zaynich—an antibiotic for treatment of complicated UTI—vindicates chairman and founder Habil Khorakiwala’s bet on ...

Novel antibiotic for difficult-to-treat urinary tract and kidney infections becomes the first drug fully developed by an ...

In an exclusive interview, Wockhardt Founder Chairman Dr. Habil Khorakiwala confirms a major transformation toward becoming a ...

The decline came despite positive commentary from Chairman Habil F Khorakiwala on the company's novel antibiotic Zaynich ...

Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and ...

Wockhardt shares fell 9% in early trade as investors booked profits following a sharp 36.77% rally driven by USFDA and CDSCO ...

Wockhardt founder and chairman Habil Khorakiwala said the company will commercialise its novel antibiotic Zaynich on its own ...

Wockhardt today announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated ...

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US ...

The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic ...

Habil F Khorakiwala, Founder & Chairman of Wockhardt Group, said the company continues to see a global peak sales opportunity ...